Day One Biopharmaceuticals, Inc. (DAWN)

The company's stock price was impacted by several events. Q2 2025 earnings led to a stock price drop, while Q3 2025 earnings and increased OJEMDA revenue resulted in a slight decline. The announcement of the Mersana Therapeutics acquisition, presentation of OJEMDA Phase 2 data, and strong Q3 earnings caused a stock surge. The completion of the Mersana Therapeutics acquisition and strong preliminary revenue for OJEMDA further boosted investor confidence. The stock has shown volatility, and insider selling was noted.

Demand seasonality for Day One Biopharmaceuticals' products has been observed, with a dip in January and a rebound in April. This pattern may be influenced by the resetting of insurance deductibles at the beginning of the calendar year.

Day One Biopharmaceuticals, Inc. is focused on developing and commercializing targeted therapies for genetically defined cancers, primarily in pediatric patients. Its key product, OJEMDA (tovorafenib), is an oral kinase inhibitor in clinical trials for pediatric low-grade glioma and received accelerated FDA approval in April 2024. Other pipeline candidates include pimsertib, DAY301, a VRK1 Inhibitor, and Emi-Le (emiltatug ledadotin).

Day One Biopharmaceuticals, Inc. is headquartered in Brisbane, California, United States. It has a partnership with Ipsen for the ex-U.S. commercialization of Ojemda, indicating an international market reach.

Day One Biopharmaceuticals has maintained a positive brand reputation due to its scientific advancements and patient-centric approach. Positive feedback from the medical community, a focus on pediatric oncology, and the FDA approval of OJEMDA have enhanced its credibility. The successful commercial launch of OJEMDA and the acquisition of Mersana Therapeutics have further bolstered its reputation.

Day One Biopharmaceuticals, Inc. has 324 institutional owners and shareholders holding a total of 95,604,377 shares. Major institutional owners include Fmr Llc, BlackRock, Inc., Atlas Venture Life Science Advisors, LLC, Vanguard Group Inc, Deerfield Management Company, L.p., Franklin Resources Inc, Rubric Capital Management LP, State Street Corp, Pictet Asset Management Holding SA, Vestal Point Capital, LP, and Access Industries, Inc. Company executives have engaged in stock selling activities.